Abstracts Archive - Page 1206 of 2425 - ACR Meeting Abstracts

Abstract Number: 6 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcomes in a Cohort of Women with Antiphospholipid Syndrome. 25- Years Long-Term Observation
Dana Tegzova¹, Katerina Andelova², Iva Kucerova², Vera Vlasakova³, Stejskal Jan⁴, Putova Ivana⁵, Marta Olejarova⁶ and Ctibor Dostál⁷, ¹Clinical Department, Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic, ²Institute of Mother and Child Care, Prague, Prague, Czech Republic, ³Dept.of Internal Medicine, City Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic, ⁴1st Medical Faculty, Dpt. of Pathology, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology, Dpt. of Immunology, Prague, Czech Republic, ⁶Clinical, Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic, ⁷Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic
Background/Purpose: The goal of this long-term project was to investigate the course of pregnancy in patients with APS (primary or secondary with SLE) in 1993-2017,…
Abstract Number: 7 • 2017 ACR/ARHP Annual Meeting
Predictive Value for Thrombosis of Double or Triple Positivity in Secondary APS Depends on the Component Assays and the Type of Thrombosis
Michelle Petri¹, Daniel Goldman² and Laurence S Magder³, ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: The lupus anticoagulant (LAC) is individually the antiphospholipid antibody (aPL) most associated with thrombotic risk in both primary and secondary APS. Anticardiolipin (aCL) and…
Abstract Number: 8 • 2017 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Leukocytes Demonstrate Increased Adhesive Potential: a Search for Novel Therapeutic Targets
Gautam Sule¹, William J. Kelley¹, Srilakshmi Yalavarthi¹, Alison Banka¹, Omolola Eniola-Adefeso¹ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²., University of Michigan, Ann Arbor, MI
Background/Purpose: Adhesion of leukocytes to the endothelium is an initiating event in the thrombosis inherent to antiphospholipid syndrome (APS). Over the years, a number of…
Abstract Number: 9 • 2017 ACR/ARHP Annual Meeting
Renal Protective Effect of Antiplatelet Therapy in Antiphospholipid Antibody-Positive Lupus Nephritis Patients without the Antiphospholipid Syndrome
Hironari Hanaoka¹, Tomofumi Kiyokawa¹, Harunobu Iida¹, Yukiko Takakuwa¹, Takahiro Okazaki², Hidehiro Yamada³, Shoichi Ozaki⁴ and Kimito Kawahata¹, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ³Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan, ⁴Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Lupus nephritis (LN) class III or IV is associated with a poor prognosis for both patient and renal survival. Since antiphospholipid syndrome (APS) is…
Abstract Number: 10 • 2017 ACR/ARHP Annual Meeting
Arterial Events in Primary Antiphospholipid Syndrome Are Associated with High Values of the Adjusted Global Antiphospholipid Syndrome Score
Flavio Signorelli¹, Gustavo G M Balbi², Roger A. Levy² and Savino Sciascia³, ¹Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: The adjusted Global AntiPhospholipid Syndrome Score (aGAPSS) was described as a tool to estimate the risk of thromboses in patients with APS. The aim…
Abstract Number: 11 • 2017 ACR/ARHP Annual Meeting
Possible Therapeutics for Antiphospholipid Antibody Related Thrombocytopenia: A Systemic Review and Meta-Analysis
Nobuya Abe¹, Kenji Oku¹, Olga Amengual¹, Yuichiro Fujieda¹, Masaru Kato¹, Toshiyuki Bohgaki¹, Shinsuke Yasuda¹, Rintaro Mori², Eriko Morishita³, Katsue Suzuki-Inoue⁴ and Tatsuya Atsumi¹, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Department of Health Policy, National Center for Child Health and Development, Tokyo, Japan, ³Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan, ⁴Department of Clinical and Laboratory Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
Background/Purpose: Despite the pro-thrombotic nature of antiphospholipid antibodies (aPL), thrombocytopenia is frequently observed in patients with antiphospholipid syndrome (APS) or in non-APS patients with aPL.…
Abstract Number: 12 • 2017 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository Analysis: Pregnancy Outcomes Since Inception
Ecem Sevim¹, Danieli Andrade², Alessandra Banzato³, D. Ware Branch⁴, Ricard Cervera⁵, Guilherme Ramires de Jesus⁶, Jason S. Knight⁷, Pier Luigi Meroni⁸, Maria Tektonidou⁹, Angela Tincani¹⁰, Amaia Ugarte¹¹, Zhang Zhuoli¹², Doruk Erkan¹³ and , on Behalf of APS ACTION .¹⁴, ¹Umraniye Research and Training Hospital, Istanbul Health Sciences University, Istanbul, Turkey, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., Sao Paulo, Brazil, ³Department of Cardiac Thoracic and Vascular Sciences, Clinical Cardiology, Thrombosis Centre, University of Padova, Padova, Italy, ⁴Obstetrics and Gynecology, University of Utah and Intermountain Healthcare, Salt Lake City, UT, ⁵Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁶Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁷., University of Michigan, Ann Arbor, MI, ⁸Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, ⁹First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, ¹⁰Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ¹¹Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Biscay, Spain, ¹²Department of Rheumatology and Immunology,Peking University First Hospital, Peking University First Hospital, Beijing, China, ¹³Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ¹⁴., New York, NY
Background/Purpose: APS ACTION Clinical Database and Repository (‘‘Registry’’) was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)…
Abstract Number: 13 • 2017 ACR/ARHP Annual Meeting
Epidemiology of Antiphospholipid Syndrome: A Population-Based Study
Ali Duarte-Garcia¹, Michael Pham¹, Cynthia S. Crowson², Kevin Moder³, Rajiv Pruthi⁴ and Eric L. Matteson⁵, ¹Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, R, MN, ⁵Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: The epidemiology of definite antiphospholipid syndrome (APS) in the general population has not been described. A recent meta-analysis (Andreoli L, et al. Arth Care…
Abstract Number: 14 • 2017 ACR/ARHP Annual Meeting
Abnormalities in Th1, Th2 and Th17 Lymphoid Subpopulations in Long-Term Evolution Primary Antiphospholipid Syndrome
Gabriela Medina¹, Oscar I Florez-Durante², Laura Arcelia Montiel Cervantes³, Rubiraida Molina Aguilar², Elba Reyes Maldonado² and Luis J. Jara⁴, ¹Clinical Research Unit, Hospital de Especialidades Centro Medico La Raza,IMSS, Mexico City, Mexico, ²Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico, ³Hematology Laboratory, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, ⁴Direction of Education and Research, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico
Background/Purpose: Primary antiphospholipid antibody syndrome (PAPS) is characterized by recurrent thrombosis and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). Lymphoid subpopulations and innate…
Abstract Number: 15 • 2017 ACR/ARHP Annual Meeting
Methodology and Systematic Review of the Literature for the Mcmaster RARE-Best Practice Clinical Practice Guideline on Diagnosis and Management of the Catastrophic Antiphospholipid Syndrome
Kimberly Legault¹, Christopher Hillis¹, Cindy Yeung¹, Elie Akl², Marc Carrier³, Ricard Cervera⁴, Mark Crowther¹, Francesco Dentali⁵, Doruk Erkan⁶, Gerard Espinosa⁷, Munther A Khamashta⁸, Joerg Meerpohl⁹, Karen Moffatt¹⁰, Sarah O'Brien¹¹, Vittorio Pengo¹², Jacob Rand¹³, Ignasi Rodriguez¹⁴, Lisa Thom¹⁵, Holger Schunemann¹ and Alfonso Iorio¹, ¹McMaster University, Hamilton, ON, Canada, ²American University of Beirut, Beirut, Lebanon, ³University of Ottawa, Ottawa, ON, Canada, ⁴Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Insubria University, Insubria, Italy, ⁶Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ⁷Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ⁸Graham Hughes Lupus Research Laboratory, The Rayne Institute, London, United Kingdom, ⁹University of Freiburg, Freiburg, Germany, ¹⁰Hamilton Health Sciences, Hamilton, ON, Canada, ¹¹Nationwide Children's, Columbus, OH, ¹²Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ¹³NY Presbyterian Hospital, New York, NY, ¹⁴Rheumatology, Hospital Clinica, Barcelona, Spain, ¹⁵None (patient representative), Oxford, United Kingdom
Background/Purpose: Catastrophic antiphospholipid syndrome (CAPS), a rare disease, is characterized by the rapid onset of widespread thrombosis associated with multi-organ failure in patients meeting the…
Abstract Number: 16 • 2017 ACR/ARHP Annual Meeting
Anti-Phosphatidylserine/Prothrombin Antibodies in Primary Antiphospholipid Syndrome
Paola Bermudez-Bermejo¹, Gabriela Hernandez-Molina², Diego Hernández-Ramírez³, Victor Zamora-Legoff², Elizabeth Olivares-Martínez³, Antonio R. Cabral⁴ and Carlos Núñez-Álvarez⁵, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición SZ, mexico city, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁴Department of Medicine. Division of Rheumatology, The Ottawa Hospital.University of Ottawa, Ottawa, ON, Canada, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico
Background/Purpose: Several studies have showed conflicting results regarding the presence and meaning of anti-phosphatidylserine/prothrombin (aPS/PT). However aPS/PT antibodies seem to be a risk factor for…
Abstract Number: 17 • 2017 ACR/ARHP Annual Meeting
Thrombotic Events in Pediatric Systemic Lupus Erythematosus: A Preliminary Analysis of a Large, Single-Center Cohort
Jennifer Rammel¹, Martha Curry² and Marietta M. de Guzman³, ¹Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ³Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: While pediatric systemic lupus erythematosus (pSLE) represents only 20% of all SLE cases, pSLE patients often have more aggressive disease with multi-organ involvement. These…
Abstract Number: 18 • 2017 ACR/ARHP Annual Meeting
Increased Frequency of Nailfold Videocapillaroscopy Abnormalities in Primaryantiphospolipid (PAPS) Patients
Tatiana Sofia Rodriguez-Reyna¹, Eduardo Martín Nares², Paola Bermudez-Bermejo³, Victor Zamora-Legoff⁴ and Gabriela Hernandez-Molina⁵, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico, ⁴Rheumatology and Immunology, Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico D.F., Mexico, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición SZ, mexico city, Mexico
Background/Purpose: Primary antiphospholipid syndrome (PAPS) is characterized by venous and arterial thrombosis, obstetric morbidity and the presence of antiphospholipid antibodies. The utility of nailfold videocapillaroscopy…
Abstract Number: 19 • 2017 ACR/ARHP Annual Meeting
The Transcription Factor Specificity Protein 1 up-Regulates IL-21 Receptor Expression on B Cells in Rheumatoid Arthritis Leading to Altered Cytokine Production and Maturation
Elizabeth Dam¹, Alison Maier¹, Anne Hocking¹, Jeffrey Carlin² and Jane H. Buckner¹, ¹Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Rheumatology, Virginia Mason Medical Center, Seattle, WA
Background/Purpose: Growing evidence suggests that IL-21 has a role in B cell dysfunction in rheumatoid arthritis (RA). Previous studies have reported that IL-21 levels are…
Abstract Number: 20 • 2017 ACR/ARHP Annual Meeting
Low Molecular Weight BAFF Receptor Antagonists Restrain Infiltration of B Cells into Organs of Autoimmune Model Mice By Suppressing B Cell Activation
Keiko Yoshimoto¹, Noriyasu Seki², Katsuya Suzuki³, Kunio Sugahara⁴ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²3) Research Unit/Immunology & Inflammation, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medcine, Tokyo, Japan, ⁴Research Unit/Immunology & Inflammation, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan
Background/Purpose: We have reported that soluble BAFF (sBAFF) robustly increased IL-6 production by peripheral monocytes of patients with primary Sjögren’s syndrome (pSS) and that the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].